Answers are grounded in this paper and cite their sources.
In our hospital-based registry, time of metastatic presentation and disease volume were prognostic for mHSPC pts treated with ADT. This simple prognostic classification system can aid patient counseling and future trial design.
No takes yet. Share an insight, caveat, or question.
Francini et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: